- Home
- EEA vs CELU Comparison
EEA vs CELU Comparison
Compare EEA & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EEA
- CELU
- Stock Information
- Founded
- EEA 1986
- CELU 2016
- Country
- EEA Germany
- CELU United States
- Employees
- EEA N/A
- CELU N/A
- Industry
- EEA Trusts Except Educational Religious and Charitable
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- EEA Finance
- CELU Health Care
- Exchange
- EEA Nasdaq
- CELU Nasdaq
- Market Cap
- EEA 67.9M
- CELU 64.3M
- IPO Year
- EEA N/A
- CELU N/A
- Fundamental
- Price
- EEA $10.66
- CELU $2.11
- Analyst Decision
- EEA
- CELU Buy
- Analyst Count
- EEA 0
- CELU 1
- Target Price
- EEA N/A
- CELU $6.00
- AVG Volume (30 Days)
- EEA 9.2K
- CELU 118.0K
- Earning Date
- EEA 01-01-0001
- CELU 08-29-2025
- Dividend Yield
- EEA 1.92%
- CELU N/A
- EPS Growth
- EEA N/A
- CELU N/A
- EPS
- EEA N/A
- CELU N/A
- Revenue
- EEA N/A
- CELU $44,590,000.00
- Revenue This Year
- EEA N/A
- CELU $23.29
- Revenue Next Year
- EEA N/A
- CELU N/A
- P/E Ratio
- EEA N/A
- CELU N/A
- Revenue Growth
- EEA N/A
- CELU 4.45
- 52 Week Low
- EEA $7.45
- CELU $1.00
- 52 Week High
- EEA $9.26
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- EEA 58.73
- CELU 32.18
- Support Level
- EEA $10.42
- CELU $2.23
- Resistance Level
- EEA $10.83
- CELU $4.00
- Average True Range (ATR)
- EEA 0.19
- CELU 0.32
- MACD
- EEA -0.01
- CELU -0.22
- Stochastic Oscillator
- EEA 60.33
- CELU 4.23
About EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.